lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-27 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
== Diagnosis == Source: Diagnosis is based on history, clinical signs, and diagnostic tests. Glucose levels alone are insufficient to diagnose EMS. Many EMS horses will effectively compensate their insulin response even with insulin resistance, maintaining a blood glucose within normal limits, although usually at the high end of normal. Other factors, such as stress, feeding, inflammation, or administration of α-2 agonist drugs such as xylazine and detomidine, can falsely raise blood glucose levels. Horses with persistent hyperglycemia may have type II diabetes. Insulin normally increases after feeding, as well as secondary to cortisol (stress) and epinephrine (pain), so measurement should be avoided if any of these conditions are present. Actively laminitic horses should therefore not undergo testing until their pain and stress have been adequately controlled. Additionally, resting insulin levels may not be increased in all animal with EMS. For these reasons, dynamic tests are recommended for the diagnosis of EMS. Measurement of fasting insulin concentration involves giving a horse a single flake of hay, low in non-structural carbohydrates, at 10 pm the night before testing. Blood being drawn the following morning, usually between 8 and 10 am. Both insulin and glucose blood levels are measured. Hyperinsulinemia suggests insulin resistance. This test is easy to perform, but is less sensitive than the oral sugar test. It is best used in cases where risks of laminitis make the oral sugar test potentially unsafe.
== Applications == Proximity labeling methods have been used to study the proteomes of biological structures that are otherwise difficult to isolate purely and completely, such as cilia, mitochondria, postsynaptic clefts, p-bodies, stress granules, and lipid droplets. Fusion of APEX2 with G-protein coupled receptors (GPCRs) allows for both tracking GPCR signaling at a 20-second temporal resolution and also identification of unknown GPCR-linked proteins. Proximity labeling has also been used for transcriptomics and interactomics. In 2019, Alice Ting and the Ting lab have used APEX to identify RNA localized to specific cellular compartments. In 2019, BioID has been tethered to the beta-actin mRNA transcript to study its localization dynamics. Proximity labeling has also been used to find interaction partners of heterodimeric protein phosphatases, of the miRISC (microRNA-induced silencing complex) protein Ago2, and of ribonucleoproteins.
Grace pleads for his understanding of her actions and then tells him of her mother's involvement in necromancy and her plans against Nephilim. She forces her bracelet back on his wrist and asks that he go to Blackthorn Manor to destroy an automaton there. With the bracelet's control strengthened, James agrees and in the process of destroying it, burns down the manor. At the following council meeting, Tatiana accuses James of having orchestrated the Mandikhor attacks and then burning her house down to destroy her evidence. In an effort to protect him, Cordelia provides him with an alibi, claiming he had been with her the night before, tarnishing her reputation. While Tatiana is being arrested and sent to the Adamant Citadel for the dark magic items found in the rubble of her home, James proposes to Cordelia in order to save her reputation, with the plan to divorce in a year, and Cordelia agrees. At James and Cordelia's engagement party, Matthew drinks heavily in an attempt to drown his sorrows, realizing he is in love with Cordelia. Charles announces his engagement to Grace and later seeks out Alastair, who breaks up with him in a lone corridor with Cordelia there to support him. Because of his drunken state, Matthew reveals the rumors Alastair had spread about their parents to Thomas, in an effort to prevent their friendship, causing Thomas to threaten Alastair, who runs out of the room crying. Ariadne approaches Anna, telling her that she heard her when she spoke to her at the infirmary, making Ariadne realize that Anna still loved her.
=== Short-term effects === The EMCDDA reported mephedrone can cause various unintended side effects including dilated pupils, poor concentration, teeth grinding, problems focusing visually, poor short-term memory, hallucinations, delusions, and erratic behaviour. They noted the most severe effects appear anecdotally to be linked with high doses or prolonged use, and the effects may be due to users taking other intoxicants at the same time. Other effects users in internet forums have noted include changes in body temperature, increased heart rate, breathing difficulties, loss of appetite, increased sweating, discolouration of extremities, anxiety, paranoia and depression. When snorted, it can also cause nose bleeds and nose burns. A survey conducted by the UK National Addiction Centre found 67% of mephedrone users experienced sweating, 51% suffered from headaches, 43% from heart palpitations, 27% from nausea and 15% from cold or blue fingers, indicative of vasoconstriction occurring. Doctors at Guy's Hospital in London reported that of 15 patients they treated after taking mephedrone in 2009, 53% were agitated, 40% had increased heart rates, 20% had systolic hypertension and 20% had seizures; three required treatment with benzodiazepines, predominantly to control their agitation. They reported none of their patients suffered from cold or blue peripheries, contrary to other reports.
Sources: en.wikipedia.org
Cocaine is an SNDRI. Cocaine is made from the leaves of the coca shrub, which grows in the mountain regions of South American countries such as Bolivia, Colombia, and Peru, regions in which it was cultivated and used for centuries mainly by the Aymara people. In Europe, North America, and some parts of Asia, the most common form of cocaine is a white crystalline powder. Cocaine is a stimulant but is not normally prescribed therapeutically for its stimulant properties, although it sees clinical use as a local anesthetic, in particular in ophthalmology. Most cocaine use is recreational and its abuse potential is high (higher than amphetamine), and so its sale and possession are strictly controlled in most jurisdictions. Other tropane derivative drugs related to cocaine are also known such as troparil and lometopane but have not been widely sold or used recreationally.
Jemima Goldsmith (born 30 January 1974) screenwriter, television, film and documentary producer and the founder of Instinct Productions, a television production company; formerly journalist and editor of The New Statesman, served as the European editor-at-large for the American magazine Vanity Fair. Jonathan Goldstein (businessman), solicitor, entrepreneur, journalist and op-ed writer for The Jewish Chronicle; co-founder of multinational investment firm Cain; director and co-owner of Chelsea; chair of Jewish Leadership Council, for which he has been vocal spokesman, and critic of Labour leader Jeremy Corbyn, in media and while addressing a rally outside of Parliament, in March 2018. Jonny Gould; media presenter, sports journalist, and political commentator; has broadcast on Sky News, Smooth Radio, and Talksport; has commented on antisemitism, conservative politics, and the state of Israel across a number of outlets including his own Jonny Gould's Jewish State podcast; his brother Ash is former producer and long-term co-presenter of James Whale. Dominic Green (writer and musician)(born 1970) journalist for The Jewish Chronicle, The Spectator and a commissioning editor of The Critic. He is a columnist and film reviewer for The Spectator, and a columnist for The Daily Telegraph. He also writes frequently on books and arts for The Wall Street Journal, The New Criterion, The Spectator (UK), Standpoint, The Literary Review, and The Oldie. He has also written for The Atlantic, Commentary, The Economist, First Things, The Weekly Standard, CapX and the antiquities magazine Minerva.
== History == The market-leading RAST methodology was invented and marketed in 1974 by Pharmacia Diagnostics AB, Uppsala, Sweden, and the acronym RAST is actually a brand name. In 1989, Pharmacia Diagnostics AB replaced it with a superior test named the ImmunoCAP Specific IgE blood test, which literature may also describe as: CAP RAST, CAP FEIA (fluorenzymeimmunoassay), and Pharmacia CAP. A review of applicable quality assessment programs shows that this new test has replaced the original RAST in approximately 80% of the world's commercial clinical laboratories, where specific IgE testing is performed. The newest version, the ImmunoCAP Specific IgE 0–100, is the only specific IgE assay to receive FDA approval to quantitatively report to its detection limit of 0.1kU/L. This clearance is based on the CLSI/NCCLS-17A Limits of Detection and Limits of Quantitation, October 2004 guideline.The guidelines for diagnosis and management of food allergy issues by the National Institute of Health state that: In 2010 the United States National Institute of Allergy and Infectious Diseases recommended that the RAST measurements of specific immunoglobulin E for the diagnosis of allergy be abandoned in favor of testing with more sensitive fluorescence enzyme-labeled assays.
== Structure == Some brands may have a pellet (spheroid) formulations (made by extrusion and spheronization) can be used for controlled release of the drug in the body whereas powder filled pellets generally cannot. The plastic spheres containing powder have micropores that open at varying pH levels, to maintain a mostly constant release during transit through the digestive tract. The spheres themselves, the outer shells, pass undigested in most patients. Other brands are thought to use ethylcellulose coatings to control drug release from pellets. Another use these medications have is that they can be given via NG tube, the pellets being very small. This makes them one of the few extended release oral medications that can be given by feeding tube.
This urge EPI to create a strategy to encompasses both vaccines and medicines to be able to sustain their components without the need of storage. The term 'cold chain' has now been replaced with 'supply chain'. The current system of vaccine cold chain still continues for delivering particular vaccines. WHO has made improvements by introducing the "controlled temperature chain" (CTC), which is an innovative approach allowing the vaccine to be taken out of the cold chain for a limited period of time, but CTC is still in the development process and will not be available for all vaccines for many years. Nowadays, engineers is still thinking of a way to eliminate refrigeration at +2 to +8C from the entire supply chain for all vaccines. With the initiatives of reducing temperature sensitivity of vaccines and regulation permits, it could eliminate the need for refrigeration in the supply chain. It will be suitable for an undeveloped country as less handling of vaccines needs to be done.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.